Tough transparency rules could harm innovation, researchers warn

04/18/2013 | MassDevice.com (Boston)

FDA premarket approval submissions are more often backed by patents produced by physician-owned startups than patents from nonphysician-owned startups, a Wolters Kluwer Health study finds. Researchers warn that enforcing burdensome financial disclosure rules could deter medtech firms from investing in physician-owned startups, which could hurt innovation.

View Full Article in:

MassDevice.com (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ